Bronchiectasis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bronchiectasis – Drugs In Development, 2024 report and make more profitable business decisions.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories: cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. Causes of bronchiectasis include inhaling a foreign object, cystic fibrosis, GERD, and a weakened immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants, and mucolytic agents.
The Bronchiectasis drugs in development market research report provide comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bronchiectasis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bronchiectasis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bronchiectasis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bronchiectasis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adiso Therapeutics IncArmata Pharmaceuticals Inc
BioAegis Therapeutics Inc
Boehringer Ingelheim International GmbH
Chiesi Farmaceutici SpA
Cila Therapeutics
CSL Ltd
Grifols SA
Haisco Pharmaceutical Group Co Ltd
Helperby Therapeutics Group Ltd
Insmed Inc
Joincare Pharmaceutical Group Industry Co Ltd
Kamada Pharmaceuticals
MDI Therapeutics Inc
Metagone Biotech Inc
NeuImmune Inc
OrPro Therapeutics Inc
Parion Sciences Inc
PureIMS BV
Reistone Biopharma Co Ltd
Renovion Inc
SolAeroMed Inc
SpliSense Ltd
Suzhou Regend Therapeutics Co Ltd
Therapeutic Systems Research Laboratories Inc
Vast Therapeutics Inc
Verona Pharma Plc
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bronchiectasis reports